These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

866 related articles for article (PubMed ID: 29183287)

  • 41. Trends and factors in human immunodeficiency virus and/or hepatitis C virus testing and infection among injection drug users newly entering methadone maintenance treatment in Guangdong Province, China 2006-2013: a consecutive cross sectional study.
    Liu Y; Liu Y; Zou X; Chen W; Ling L
    BMJ Open; 2017 Jul; 7(7):e015524. PubMed ID: 28710214
    [TBL] [Abstract][Full Text] [Related]  

  • 42. HIV prevalence and risk behaviors among people who inject drugs in two serial cross-sectional respondent-driven sampling surveys, Zanzibar 2007 and 2012.
    Matiko E; Khatib A; Khalid F; Welty S; Said C; Ali A; Othman A; Haji S; Kibona M; Kim E; Broz D; Dahoma M
    AIDS Behav; 2015 Feb; 19 Suppl 1(Suppl 1):S36-45. PubMed ID: 25399032
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hepatitis B and C Co-Infections in Some HIV-Positive Populations in Cameroon, West Central Africa: Analysis of Samples Collected Over More Than a Decade.
    Noubiap JJ; Aka PV; Nanfack AJ; Agyingi LA; Ngai JN; Nyambi PN
    PLoS One; 2015; 10(9):e0137375. PubMed ID: 26371878
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Co-infections of hepatitis B and C with human immunodeficiency virus among adult patients attending human immunodeficiency virus outpatients clinic in Benin City, Nigeria.
    Ojide CK; Kalu EI; Ogbaini-Emevon E; Nwadike VU
    Niger J Clin Pract; 2015; 18(4):516-21. PubMed ID: 25966725
    [TBL] [Abstract][Full Text] [Related]  

  • 45. HIV and hepatitis C prevalence, and related risk behaviours among people who inject drugs in three cities in Croatia: Findings from respondent-driven sampling surveys.
    Handanagic S; Bozicevic I; Civljak M; Dominkovic Z; Sevic S; Barbaric J; Nemeth Blazic T; Dakovic Rode O; Begovac J
    Int J Drug Policy; 2016 Jun; 32():57-63. PubMed ID: 27160504
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Overt and occult hepatitis B virus infection in adult Sudanese HIV patients.
    Mudawi H; Hussein W; Mukhtar M; Yousif M; Nemeri O; Glebe D; Kramvis A
    Int J Infect Dis; 2014 Dec; 29():65-70. PubMed ID: 25449238
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prevalence of HIV and other infections and correlates of needle and syringe sharing among people who inject drugs in Podgorica, Montenegro: a respondent-driven sampling survey.
    Lausevic D; Begic S; Mugosa B; Terzic N; Vratnica Z; Labovic I; Bozicevic I
    Harm Reduct J; 2015 Feb; 12():2. PubMed ID: 25884194
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prevalence of hepatitis B and C among HIV positive patients in Georgia and its associated risk factors.
    Badridze N; Chkhartishvili N; Abutidze A; Gatserelia L; Sharvadze L
    Georgian Med News; 2008 Dec; (165):54-60. PubMed ID: 19124918
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Epidemiological Profile and Risk Factors for Acquiring HBV and/or HCV in HIV-Infected Population Groups in Nepal.
    Bhattarai M; Baniya JB; Aryal N; Shrestha B; Rauniyar R; Adhikari A; Koirala P; Oli PK; Pandit RD; Stein DA; Gupta BP
    Biomed Res Int; 2018; 2018():9241679. PubMed ID: 29487874
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hepatitis C care continuum and associated barriers among people who inject drugs in Chennai, India.
    Patel EU; Solomon SS; Mcfall AM; Srikrishnan AK; Pradeep A; Nandagopal P; Laeyendecker O; Tobian AAR; Thomas DL; Sulkowski MS; Kumar MS; Mehta SH
    Int J Drug Policy; 2018 Jul; 57():51-60. PubMed ID: 29679811
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prevalence of HIV, HCV and HBV infection and sociodemographic characteristics of people who inject drugs in China: A systematic review and meta-analysis.
    Bao Y; Larney S; Peacock A; Colledge S; Grebely J; Hickman M; Degenhardt L; Leung J
    Int J Drug Policy; 2019 Aug; 70():87-93. PubMed ID: 31125802
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prevalence of hepatitis C and hepatitis B infection in the HIV-infected population of France, 2004.
    Larsen C; Pialoux G; Salmon D; Antona D; Le Strat Y; Piroth L; Pol S; Rosenthal E; Neau D; Semaille C; Delarocque Astagneau E
    Euro Surveill; 2008 May; 13(22):. PubMed ID: 18761958
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cross sectional study of factors associated to self-reported blood-borne infections among drug users.
    Reyes-Urueña J; Brugal MT; Majo X; Domingo-Salvany A; Caylà JA
    BMC Public Health; 2015 Nov; 15():1122. PubMed ID: 26566634
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Understanding hepatitis B, hepatitis C and HIV among people who inject drugs in South Africa: findings from a three-city cross-sectional survey.
    Scheibe A; Young K; Moses L; Basson RL; Versfeld A; Spearman CW; Sonderup MW; Prabdial-Sing N; Manamela J; Puren AJ; Rebe K; Hausler H
    Harm Reduct J; 2019 Apr; 16(1):28. PubMed ID: 30975139
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Role of unsafe medical practices and sexual behaviours in the hepatitis B and C syndemic and HIV co-infection in Rwanda: a cross-sectional study.
    Makuza JD; Nisingizwe MP; Rwema JOT; Dushimiyimana D; Habimana DS; Umuraza S; Serumondo J; Ngwije A; Semakula M; Gupta N; Nsanzimana S; Janjua NZ
    BMJ Open; 2020 Jul; 10(7):e036711. PubMed ID: 32660951
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Hepatitis C infection and other drug-related harms among inpatients who injected drugs in Turkey.
    Alaei A; Alaei K; Waye K; Tracy M; Nalbandyan M; Mutlu E; Cetin MK
    J Viral Hepat; 2017 Jun; 24(6):496-505. PubMed ID: 27925346
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prevalence of hepatitis B virus, hepatitis C virus, human immunodeficiency virus and Treponema pallidum infections in hospitalized patients before transfusion in Xiangya hospital Central South University, China from 2011 to 2016.
    Cao WW; Zhou RR; Ou X; Shi LX; Xiao CQ; Chen TY; Tan H; Fan XG; Li BJ; Li N
    BMC Infect Dis; 2018 Apr; 18(1):145. PubMed ID: 29606088
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prevalence, estimated incidence, risk behaviours, and genotypic distribution of hepatitis C virus among people who inject drugs accessing harm-reduction services in Kenya: a retrospective cohort study.
    Akiyama MJ; Cleland CM; Lizcano JA; Cherutich P; Kurth AE
    Lancet Infect Dis; 2019 Nov; 19(11):1255-1263. PubMed ID: 31540840
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Community seroprevalence of hepatitis B, C and human immunodeficiency virus in adult population in gojjam zones, northwest Ethiopia.
    Abera B; Adem Y; Yimer M; Mulu W; Zenebe Y; Mekonnen Z
    Virol J; 2017 Feb; 14(1):21. PubMed ID: 28166829
    [TBL] [Abstract][Full Text] [Related]  

  • 60. An urgent need to scale-up injecting drug harm reduction services in Tanzania: prevalence of blood-borne viruses among drug users in Temeke District, Dar-es-Salaam, 2011.
    Bowring AL; Luhmann N; Pont S; Debaulieu C; Derozier S; Asouab F; Toufik A; van Gemert C; Dietze P; Stoove M
    Int J Drug Policy; 2013 Jan; 24(1):78-81. PubMed ID: 23036650
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 44.